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Neuropathological changes of Alzheimer’s disease (AD)
evolve several years before the onset of clinical symptoms
[1,2]. Therefore, it is believed that characterization of
earlier stages of AD, that is, mild cognitive impairment
(MCI) and subjective cognitive decline (SCD), could beget
new strategies to diagnose and treat the disease earlier [3].
An SCD population represents a subset of cognitively
normal individuals with self-reported cognitive impairment
[4]. It is suggested that a prodromal AD subgroup could be
nested in an SCD population. Nevertheless, there is a scar-
city of research studying both genetic and biomarker profiles
of SCD individuals. New studies might help to improve the
identification of those SCD individuals at risk of AD.
Thus far, presence of the apolipoprotein E (APOE) ε4
allele, the major genetic risk factor for AD [5], has been
the only genetic marker associated with risk of SCD [6].
In a previous meta-analysis with 6824 individuals, we
were able to estimate that APOE ε4 was significantly associ-
ated with risk of SCD [odds ratio [OR] 5 1.15 (1.02–1.30);
P 5 .03] [6]. Although the contribution of other genes has
been explored, that is, IL1B or TNF [7], the risk of presenting
an SCD diagnosis or of converting from SCD to AD has not
been associated with other genetic signals [7,8].
Traditional AD-biomarker research has been focused on as-
sessing cerebral amyloid aggregation and neuronal pathology,
both of which are considered classical neuropathological hall-
marks of AD [9]. It has been demonstrated that APOE alleles
contribute to thebiologicalmodulationof amyloidb (Ab) clear-
ance [10]. Furthermore, genome-wide association studies
(GWASs) evaluating the cerebral amyloid burden endopheno-
type have reinforced APOE’s role in amyloid accumulation
[11,12]. Despite the inextricable link between APOE and Ab
burden in AD patients, none of the reported endophenotype
GWASs included SCD cohorts [11,12]. Thus, APOE’s role in
amyloid burden in the SCD population remains poorly
examined.
Several studies have detected higher cerebral amyloid
burden in AD and MCI patients compared with cognitively
normal individuals [13–15] and also in AD compared with
MCI patients [13], but studies evaluating amyloid pathology
in SCD have provided inconsistent results [15,16]. However,
when APOE genotypes are considered, more predictable
results are observed, that is, SCD individuals who are APOE
ε4 carriers have shown higher amyloid positron emission
tomography (PET) uptake than SCD or healthy control ε4noncarriers [17]. Understanding genetic and biomarker pro-
files, aswell as their interaction, inSCD individuals,will allow
integration of multiple variables influencing AD risk, that is,
APOE status, age, and amyloid burden, and enhance the
discrimination of subjects at risk of conversion to AD.
Here, we analyze APOE genotypes, baseline cerebral am-
yloid profile, and their relationship in the Fundacio ACE
Healthy Brain Initiative (FACEHBI) cohort, which included
200 SCD individuals enrolled in a long-term longitudinal
study of cognition, biomarkers, and lifestyle [18]. We eval-
uated APOE ε4’s effect in the risk of presenting SCD using
a case-control design including the FACEHBI SCD cohort
and a cohort of Spanish population-based controls and after-
ward by performing a meta-analysis including studies ad-
dressing the same question. To explore whether SCD
individuals who carry the APOE ε4 allele present increased
risk of MCI or AD compared with noncarrier SCD individ-
uals, we calculated ORs using Fundacio ACE SCD, MCI,
and AD cohorts. To explore the relationship between
APOE and brain amyloid burden, first we analyzed the
FACEHBI data and then extended the analysis by including
an independent cohort from the Alzheimer’s Disease Neuro-
imaging Initiative (ADNI) study. Finally, we explored
whether the effect of APOE dosage on brain amyloid burden
was homogenous across clinical diagnoses (controls, SCD,
MCI, and AD) using the FACEHBI and ADNI cohorts.2. Methods
2.1. Subjects
With the objective to explore the effect ofAPOE ε4 in risk of
presenting SCD, we used 200 SCD individuals recruited from
the FACEHBI study and 3032 population-based controls re-
cruited by a cross-sectional epidemiological survey, described
below. In addition, we sought to estimate the risk conferred by
this genotype in SCD population to haveMCI orAD, using the
FACEHBI sample, the ACEMCI cohort (1170 MCI patients),
and the ACE AD cohort (2517 AD patients), all of them re-
cruited by Fundacio ACE (Supplementary Fig. 1). To avoid
population stratification, all individuals were selected to be of
white Mediterranean ancestry with registered Spanish ances-
tors (for two generations).
2.1.1. The FACEHBI cohort
The FACEHBI cohort comprises 200 individuals diag-
nosed with SCD (mean age, 65.8 6 7.1 years; 62.5%
S. Moreno–Grau et al. / Alzheimer’s & Dementia 14 (2018) 634-643636women), which are embedded in a long-term observational
study [18]. The sample has been obtained from two different
sources: individuals referred by their physicians to our mem-
ory clinic for study of cognitive impairment and individuals
who came to our institution through an Open House Initia-
tive. SCD was defined as the coexistence of cognitive com-
plaints and a score of 8 on MFE-30, the Spanish version
of the Memory Failures in Everyday Life Questionnaire
(20); Mini–Mental State Examination 27; clinical demen-
tia rating (CDR) 5 0; and performance on Fundacio ACE
Neuropsychological Battery [19] within the normal range
for age and educational level. Further description of inclusion
and exclusion criteria is provided by Rodriguez-Gomez et al
[18]. All participants gave written consent, and the protocol
was approved by the ethics committee of the Hospital Clinic
i Provincial (Barcelona, Spain) (EudraCT: 2014-000798-38).
All subjectswere screened at baseline for brain amyloidosis
with Florbetaben [18F] radio tracer using PET (FBB-PET).
PET images were acquired after administration of single
slow intravenous bolus (6 sec/mL) of 300 Mbq of FBB (Neu-
raCeq), in a total volume of up to 10 mL, during 20 minutes.
GenomicDNAwas obtained from200mLof humanwhole
blood using commercial methods. High-resolution melting
procedures were performed to determine APOE genotypes.
Polymerase chain reactions (PCRs)were carried out in a final
volume of 5mL, using 11 ng of genomicDNA, 0.3mMof each
primer, and 2.65mLof 2XSYBRFastMasterMix (KapaBio-
systems). PCR conditions were a denaturation step at 95C
for 2 minutes, 33 cycles at 95C for 10 seconds, and at
69C for 30 seconds. Melting curves were 95C for 15 sec-
onds (ramping rate 5.5C/second), 45C for 15 seconds
(ramping rate of 5.5C/second), and 95C for 15 seconds
(ramping rate of 5.5C/second). A fluorometric register
was performed at one acquisition register per each degree
Celsius. Melting peaks and genotype calls were obtained us-
ing the Eco Real-Time PCR system (Illumina).
2.1.2. The ACE MCI cohort
We included a sample of 1170 MCI patients (mean age,
75.9 6 7 years; 64.5% women) recruited and assessed at
the Fundacio ACE Diagnostic Unit (Barcelona, Spain) be-
tween January 2006 and July 2013. A diagnosis of MCI
was assigned according to Petersen criteria [20,21] and the
classification of Lopez et al. [22,23]. All subjects had a
CDR of 0.5 and were assessed using the Mini–Mental State
Examination; the Hachinski Ischemia Scale; the Bipolar
Depression Rating Scale; and the Neuropsychiatric
Inventory Questionnaire. DNA was extracted using
standard procedures, and conventional real-time PCR pro-
cedures (Applied Biosystems) were used to obtain APOE ge-
notypes. See SupplementaryMaterial from Lacour et al [24].
for detailed information.
2.1.3. The ACE AD cohort
We included 2517ADcases (mean age, 81.66 16.3 years,
70.9% women), who were referred for evaluation of cogni-tive impairment by their primary care physicians or primary
care neurologists. Diagnosis of dementia and type of demen-
tia are established by consensus according to DSM-IV
criteria for dementia and NINCDS-ADRDA criteria for
possible or probable AD. Further information of inclusion
criteria and genotyping procedures is provided by Seshadri
et al [25] and Boada et al [26].
2.1.4. Population-based controls
We used 3032 Spanish controls (mean age 54,
611.7 years, 61.8% women) with unknown cognitive sta-
tus recruited from a cross-sectional population-based
epidemiological survey to describe the prevalence of car-
diovascular risk factors in the general population, previ-
ously described [27,28]. Survey procedures were
adapted from the World Health Organization MONICA
Project (WHO MONICA) protocol. DNA extraction and
APOE genotyping procedures were previously described
by Seshadri et al [25].
2.1.5. The ADNI series
To validate our correlation analysis between APOE ge-
notypes and brain amyloid in the FACEHBI cohort in an
independent data set, we used 182 healthy controls
(HCs), 103 SCD, 460 MCI, and 144 AD participants
with available amyloid PET and APOE data from the
ADNI study (http://adni.loni.usc.edu) [29]. Informed con-
sent was obtained according to the Declaration of Hel-
sinki. The ADNI PET core processes Florbetapir [18F]
(AV45) PET images according to previously described
methods [30].
2.2. Statistical analysis and meta-analysis2.2.1. Risk analysis of the APOE locus in SCD
To investigate the effect of carrying an APOE ε4 allele in
the risk of presenting SCD, we performed allelic frequency
comparisons with a c2 test between 200 SCD individuals and
3032 Spanish population-based controls. Similarly, to
explore whether SCD individuals who are carriers of
APOE ε4 present increased risk of MCI or AD, we calcu-
lated ORs using Fundacio ACE SCD, MCI, and AD cohorts.
Logistic regression analysis (additive model) was used to
perform adjustments per (1) gender and (2) gender and
age. All statistical analyses were performed using PLINK
1.9 software (http://www.cog-genomics.org/plink2) [31].
In addition, meta-analysis techniques were used to esti-
mate the APOE ε4’s effect in the risk of presenting SCD.
We have updated a previous meta-analysis conducted by
our group, which included studies published before 2015
and a total of 6824 individuals [6], with studies published
before July 2017. Literature search in PubMed was per-
formed using APOE and SCD terms. We selected the studies
meeting the following criteria: (1) case/control studies or
longitudinal studies, where it is possible to distinguish a sub-
population of SCD individuals and a subpopulation of
S. Moreno–Grau et al. / Alzheimer’s & Dementia 14 (2018) 634-643 637healthy controls; (2) studies that provide a complete defini-
tion of the participants; and (3) studies that provided an OR
with 95% confidence interval (CI) as well as the P-value or
provide sufficient data to calculate them. Studies with over-
lapping samples were excluded. After the incorporation of
data from the FACEHBI cohort, a total of 12,183 individuals
were included (Supplementary Fig. 2). SCD definition and
recruitment strategy for each included study have been
detailed in Supplementary Table 1. Effects were determined
using the inverse variant method (fixed-effects model). In the
case of heterogeneity, the DerSimonian and Laird method
(random-effects model) was used. Heterogeneity was
considered significant when I2 . 50% and P , .05. Pooled
effects and forest and funnel plots were obtained using
Metafor package from R.
2.2.2. Effect of the APOE locus on brain amyloid burden
We used baseline individual standardized uptake value
ratios (SUVRs) from the FACEHBI and ADNI. First, we
tested for normality of FBB and AV45 global SUVR mea-
sures and found they were not normally distributed. Thus,
we decided to log-transform the data to conduct the consec-
utive analyses. APOE genotypes were codified according to
the ε4 allele dosage, that is, ε4ε4 5 2; ε3ε4 5 1; ε3ε3 5 0;
ε2ε4 5 0; ε2ε3 5 21; ε2ε2 5 22. The present analyses
were carried out using SPSS 20.0 (SPSS Statistics 20;
IBM Corporation, Somers, NY, USA).
2.2.2.1. Global SUVR according to APOE dosage in the
FACEHBI cohort
We performed an analysis of variance to look for differ-
ences in global SUVR across APOE dosage (five groups)
in the FACEHBI cohort. Post hoc analysis, including Bon-
ferroni correction for multiple comparisons, was performed
to check differences between groups. APOE ε2ε2 genotype
was not considered in post hoc testing because of its small
sample size (n 5 1). Ggplot2 package from R was used to
depict differences between groups.Table 1
Adjusted and unadjusted effects of APOE ε4 in the risk of SCD diagnosis and ris
%Genotype carriers (n) Unadjusted




















Abbreviations: AD, Alzheimer’s disease; APOE, apolipoprotein E; CI, confiden
ratio; SCD, subjective cognitive decline.2.2.2.2. The relationship between APOE dosage and brain
amyloid burden
We sought to estimate the relationship between APOE ε4
allele dosage and brain amyloid burden in the FACEHBI
SCD cohort and in an independent cohort from the ADNI.
The ADNI cohort included individuals with different clinical
diagnoses (HC 5 182, SCD 5 103, early MCI 5 303, late
MCI5 157, and AD5 144) to explore whether the relation-
ship changed across different clinical categories. Because
FACEHBI and ADNI use different radioactive tracers, we
decided to standardize log-transformed amyloid SUVR to
be able to compare results. We used linear regression model
with SUVR as the dependent variable and APOE dosage as
the independent variable, to check this correlation. Ggplot2
package from R was used to depict the individual slopes
per status. Finally, two additional methods were used to
explorewhether there was a homogeneous correlation across
differential clinical categories: (1)meta-analysis of the effect
ofAPOE ε4 on brain amyloid burden across different clinical
diagnoses; criterions for selection of the meta-analyses
model was described in Section 2.2.1. Correlation coeffi-
cients were pooled using Meta packages from R and (2) the
evaluation of an interaction term using the general linear
model across the entire sample (n 5 1089). Clinical cate-
gories were coded as follows: HC 5 0; SCD 5 1; early
MCI 5 2; late MCI 5 3; and AD 5 4.
We examined the relationship between age and brain am-
yloid burden using the same analyses described for APOE
dosage. Age at baseline was used for the present analysis.3. Results
3.1. Risk analysis of APOE locus in SCD
APOE markers (rs7412 and rs429358) followed the
Hardy Weinberg equilibrium. Enrichment in the allelic fre-
quencies of APOE ε2 and ε4 was detected in the FACEHBI
sample with respect to the control population. Genotypic andk to have MCI or AD from SCD status
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Fig. 2. Effect of APOE allele dosage in cerebral amyloid burden for the
FACEHBI cohort. Mean is represented in white. Abbreviations: APOE,
apolipoprotein E; SUVR, standardized uptake value ratio.
S. Moreno–Grau et al. / Alzheimer’s & Dementia 14 (2018) 634-643638allelic frequencies for the studied cohorts are reported in
Supplementary Table 2.
Higher risk of having SCDwas identified forHCAPOE ε4
carriers with respect to noncarriers [OR5 1.61 (1.21–2.16);
P5.001]. In the case ofAPOE ε2, a nonsignificant risk effect
was detected [OR 5 1.20 (0.82–1.77); P 5 .34] (Table 1).
Similarly, when the comparison was conducted between
SCD individuals and MCI patients, the risk of MCI was not
significantly increased in SCD subjects carriers of APOE
ε4 compared with noncarriers although a risk trend was
observed [OR5 1.28 (0.95–1.72); P5 .098] and a protective
association was detected for APOE ε2 [OR 5 0.53 (0.34–
0.82); P5 .003]. In the case of SCD individuals and AD pa-
tients, SCD individuals who are carriers of APOE ε4 present
an increased risk of AD [OR5 1.95 (1.47–2.60); P5 2.69e-
6], in contrast to APOE ε2’s effect [OR5 0.42 (0.28–0.63);
P 5 1.90e25] (Table 1). No major difference in the effect
size of APOE ε4 and APOE ε2 was detected after adjusting
for gender. After adjusting for gender and age, the effect
forAPOE ε2 inMCI andADgroups decreased and the signif-
icance level increased (Table 1). This effect was expected
taking into account that age is an independent risk factor
for AD and the presence of major differences in age among
the studied cohorts.
Themeta-analysis (n5 12,183) evaluating APOE’s effect
in the risk of presenting SCD showed increased risk of SCD
in HC carriers of the APOE ε4 allele [1.18 (1.06–1.31);
P5.002] (Fig. 1).APOE ε4’s effect show nonsignificant het-
erogeneity between studies (I25 39%, P5 .06). Funnel plot
is shown in Supplementary Fig. 3. Egger test for funnel plot
asymmetry presented a P value5 .99, supporting that publi-
cation bias is not present in ourmeta-analysis. Subpopulation
analysis only for Caucasians [1.17 (1.05–1.29); P 5 .004]
(I2 5 42%, P 5 .06) showed that the pooled effect was not
modified when additional population was introduced.Study Total               Associaon OR          95%-CI
1.15 [0.66 ̶ 2.00]
2.20 [0.90 ̶ 5.38]
1.02 [0.81 ̶ 1.28]
0.78 [0.42 ̶ 1.46]
0.80 [0.52 ̶ 1.23]
0.70 [0.13 ̶ 4.93]
2.42 [0.63 ̶ 9.33]
1.11 [0.81 ̶ 1.51]
1.17 [0.72 ̶ 1.92]
1.26 [1.05 ̶ 1.51]
2.35 [1.11 ̶ 4.97]
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APOE Study [6] 447
Czech Brain Aging Study[45] 63
IMH.Pekin [6] 92
LASA  [46] 1,168
Vallecas Project's Cohort [47] 608
NHS [6] 3,375
OPH [6] 147
PATH Through Life W1 [48] 288
F.ACE 3,232
Fig. 1. Forest plot for the effect of APOE ε4 genotype in risk to be diag-
nosed with SCD. Abbreviations: ADNI, Alzheimer’s Disease Neuroimaging
Initiative; APOE, apolipoprotein E; CI, confidence interval; OR, odds ratio;
SCD, subjective cognitive decline. For further information about Czech
brain aging study, LASA, Vallecas Study, and PATH Study, see references
[45], [46], [47] and [48], respectively.3.2. Effect of APOE locus on brain amyloid burden3.2.1. Global SUVR according to APOE dosage in the
FACEHBI cohort
Global SUVR was significantly different across APOE
dosage groups in the FACEHBI cohort. Post hoc analysis re-
vealed that those groups comprising APOE ε4 carriers were
driving this difference (Fig. 2).
3.2.2. The relationship between APOE dosage and brain
amyloid burden
APOE ε4 dosage explained 9%of the variance in brain am-
yloid burden (R2 5 0.09; P 5 1.70e25) in the FACEHBI
cohort (Table 2). When we performed the model taking into
account APOE allele dosage and age, 15% of the variance
was explained (R2 5 0.15; P 5 5.25e28). APOE ε4 dosage
explained 12% of the variance (R2 5 0.12; P 5 .004) in the
SCD ADNI cohort, which is in accordance with our findings
(Table 2). Next, we investigated the relationship between am-
yloid accumulation and APOE allele dosage across the entire
ADNI series, comprising HC, SCD, MCI, and AD cohorts.
The highest correlation was detected in late-onset MCI indi-
viduals (R2 5 0.18; P 5 2.86e28). Moreover, we observed
an upward trend in the coefficient of determination from HC
to late-onset MCI. However, the correlation experimented a
decrease when the analysis was performed in AD individuals
(R2 5 0.09; P 5 2.00e24) (Table 2). Individual slopes per
clinical categories are shown in Supplementary Fig. 4.
The meta-analysis showed that the correlation between
APOE dosage and amyloid burden was not significantly
heterogeneous across clinical groups (I2 5 7%; P 5 .372)
(Fig. 3), and APOE ε4 allele dosage explained 11% of the
variance in amyloid SUVR [R (95% CI) 5 0.33 (0.28–
0.40), P , .001; Fig. 3]. Although a significant interaction
between the effect of APOE dosage and clinical status
across the pooled data was detected (R2 5 0.27; P 5 .02),
the explained variance experimented minor changes when
Table 2
Determination coefficient and level of significance between APOE allele dosage and cerebral amyloid burden
Study ADNI FACEHBI ADNI ADNI ADNI ADNI
Status HC SCD SMC EMCI LMCI AD
N 182 200 103 303 157 144
Age (mean 6 SD) 73.4 6 6.3 65.8 6 7.1 72.2 6 5.6 71.3 6 7.4 72.2 6 7.5 74.4 6 8.1
APOE ε4 carriers % (n) 28.6 (52) 26.0 (52) 31.1 (32) 43.2 (131) 57.9 (91) 67.4 (97)
R2; P value 0.05; .002 0.09; 1.70e25 0.12; 0.004 0.14; 1.95e211 0.18; 2.86e28 0.09; 2.00e24
Abbreviations: AD, Alzheimer’s disease; ADNI, Alzheimer’s Disease Neuroimaging Initiative; APOE, apolipoprotein; EMCI, early mild cognitive impair-
ment; FACEHBI, Fundacio ACE Healthy Brain Initiative; HC, healthy control; LMCI, late mild cognitive impairment; PET, positron emission tomography;
SCD, subjective cognitive decline; SMC, subjective memory impairment; SUVR, standardized uptake value ratio.
NOTE. SUVR data used for the present analyses were obtained after the standardization of log-transformed SUVR.
S. Moreno–Grau et al. / Alzheimer’s & Dementia 14 (2018) 634-643 639the model was run without considering the interaction fac-
tor (R2 5 0.26).
Finally, we decided to explore the effect of age on am-
yloid burden. The meta-analysis of the correlation coeffi-
cient between age and amyloid burden detected highStudy Total                Corre
dosage correlation with amyloid PET
Random Effect Model 1,089
I2 = 7%, p = 0.37
I2 = 83%, p < 0.01
Age correlation with amyloid PET
HC ADNI                     182
SCD FACEHBI             200
SMC ADNI                  103
EMCI ADNI                 303              
LMCI ADNI                 157
AD ADNI                     144
-0.4     -0.2         0 
HC ADNI                     182
SCD FACEHBI             200
SMC ADNI                  103
EMCI ADNI                 303              
LMCI ADNI                 157
AD ADNI                     144
Fixed Effect Model 1,089
-0.4     -0.2        0 




Fig. 3. Forest plot for (A) the effect of APOE ε4 and (B) the age, in amyloid burde
Alzheimer’s Disease Neuroimaging Initiative; APOE, apolipoprotein; EMCI, early
tive; HC, healthy control; LMCI, late mild cognitive impairment; PET, positron
memory impairment.heterogeneity (I2 5 82.7%; P , .0001) (Fig. 3). In addi-
tion, advanced age was not correlated with higher cerebral
amyloid accumulation [R (95% CI) 5 0.11 (20.03 to
0.26); P 5 .13; Fig. 3]. A nonsignificant interaction
term was observed between age and clinical status forla on COR        95%-CI        Weight
       0.2      0.4 
       0.2      0.4 
0.18    [ 0.04; 0.31]    17.2%
0.13    [-0.06; 0.32]    15.0%
0.31    [ 0.21; 0.20]     18.2%
0.04    [-0.12; 0.20]    16.5%
-0.20   [-0.35; -0.04]    16.2%  
0.30    [ 0.17; 0.42]    18.4%
0.34    [ 0.16; 0.50]      9.3%
0.37    [ 0.27; 0.47]     28.0%
0.42    [ 0.29; 0.55]    14.4%
0.31    [ 0.15; 0.45]    13.2%  
0.11   [-0.03; 0.26]     100%
0.33    [0.28; 0.38]     100%
la on COR        95%-CI        Weight
0.22    [ 0.08; 0.36]    16.7% 
0.18    [ 0.03; 0.32]    16.9%
n across clinical categories. Abbreviations: AD, Alzheimer’s disease; ADNI,
mild cognitive impairment; FACEHBI, Fundacio ACE Healthy Brain Initia-
emission tomography; SCD, subjective cognitive decline; SMC, subjective
S. Moreno–Grau et al. / Alzheimer’s & Dementia 14 (2018) 634-643640predicting variance in brain amyloid levels (R2 5 0.19;
P 5 .18). The proportion of variance explained when
the model did not consider the interaction was 17%
(R2 5 0.17).4. Discussion
SCD has been identified as a risk factor to have AD [32]
and has been suggested as a potential preclinical stage of the
disease [33]. Despite this, the genetic and biomarker profiles
of SCD individuals remain mostly unexplored.
In this study, we report increased risk of SCD from
healthy status in carriers of the APOE ε4 allele using the
FACEHBI SCD sample, which supports that a pool of AD
patients are nested in this cohort. We performed a large
meta-analysis that demonstrated APOE ε4 is a genetic risk
factor of presenting SCD. Furthermore, APOE ε4 carriers
with SCD presented a significantly increased risk of AD
diagnosis. The finding of APOE ε2 allele enrichment in
the FACEHBI cohort (not observed in other data sets, i.e.,
ADNI) [OR (CI 95%) 5 0.53 (0.37–0.74); P 5 2.30e24]
was unexpected taking into account the protective role of
APOE ε2 in AD [34]. There could be two reasons for this.
Higher frequency of APOE ε2 allele has been detected in in-
dividuals with white matter hyperintensities [35,36]. Taking
into account that there is an increment in white matter
hyperintensities in subjects with vascular dementia [37],
the enrichment of APOE ε2 in the FACEHBI population
could be underlying a pool of subjects with brain vascular al-
terations. Random chance could also be underlying this vari-
ation in ε2 allelic frequency.
The SCD cohorts used in this meta-analysis present a
certain level of heterogeneity (I2 5 39%; P 5 .06), which
could be due to differences in the selection of SCD and
healthy controls individuals among studies. SCD comprises
individuals who will convert to AD, individuals who will
convert to other dementias, and others who will remain
healthy. Moreover, other factors could be leading to this
heterogeneity, that is, differences in recruitment strategies,
assessment [38], and SCD definitions across studies [39],
which researchers must carefully control for and stan-
dardize. In this sense, significant efforts are underway to
design neuropsychological tools sensitive to subtle cogni-
tive changes and to identify genetic and biomarker profiles
in SCD subjects. The integration of genetic, neuropsycho-
logical, and biomarker profiles seems necessary to charac-
terize SCD individuals and improve reproducibility of
studies.
In an effort to improve characterization of SCD individ-
uals, we combined APOE and amyloid burden information.
We detected statistically significant differences in cerebral
amyloid burden between APOE allele dosage stratums in
the FACEHBI sample, which is in accordance with previous
findings [40,41]. The variation in brain amyloid levels ispartially explained by APOE genotype in our series. This
finding was replicated in the ADNI data set by us and
others [11].
The contribution of other genetic factors to cortical Ab
levels remains mostly unexplored, and a large proportion
of the variance remains unexplained. Some studies describe
models that consider the contribution of other genetic
markers, that is, APOE ε4 and BCHE-rs509208 explained
15% of the variance [11] and IL1RAP-rs12053868 explained
7.1% of the variance [12]. However, when the model consid-
ered the polygenic risk score of genes identified in the stage I
of the International Genomics of Alzheimer’s Project study,
only 1% of the variance was explained [42]. The involve-
ment of nonamyloid processes in AD could be explaining
this inconsistency. Either way, it seems necessary to include
the genetic markers associated with the amyloid cascade in
the model. The finding of substantial overlap between genes
associated to AD pathology with those driving cerebral am-
yloid burden would support the use of this trait as an AD
endophenotype.
After exploring the correlation between APOE and
amyloid burden across clinical categories, a decrease in the
correlation coefficient was observed in the AD group. This
result could be explained by the effect of atrophy in amyloid
PET measurements. Some works have proposed partial-
volume effect can be distorting PET signal and diminishing
the accuracy of the measure [43]. On the other hand, a subtle
interaction effect was detected between APOE and clinical
categories predicting amyloid burden. This interaction was
not detected using the meta-analysis strategy, maybe, because
it might be underpowered. In that scenario, adjusting for clin-
ical category is mandatory when individuals with different
clinical status are merged for studying the brain amyloid
burden endophenotype with GWAS methodology.
In the same way, we also evaluated the role of age in
determining the Ab brain burden endophenotype across
the AD continuum. Age has been suggested as a nongenetic
risk factor for AD [44], and several studies have pointed to it
as a risk factor for cerebral amyloid burden [15]. Conversely,
we did not detect a correlation between age and Ab
load, and an inverse correlation was detected in the AD
group, which can be caused by partial-volume effect.
Older individuals might present an advanced stage of the dis-
ease, showing greater atrophy that could be disturbing PET
measurements. In addition, an interaction effect was not de-
tected between age and clinical category predicting the
change of amyloid burden, which is not unexpected consid-
ering that age did not modulate this endophenotype. AD is
related with both advanced age [44] and the presence of
neuritic plaques [9]. This dual association can generate a
confounding relation when age and Ab are analyzed inde-
pendently from AD. Hence, we propose that age acts as a
confounding factor, which is not directly associated with
the Ab endophenotype.
S. Moreno–Grau et al. / Alzheimer’s & Dementia 14 (2018) 634-643 641There are potential limitations in the present study. We
were not able to genotype APOE alleles at the same
moment for different cohorts. Despite that, we check
that both APOE markers (rs7412 and rs429358) were
following Hardy Weinberg expectations for each compar-
ison. In addition, to evaluate the correlation between
APOE dosage and amyloid burden, we used data from
the FACEHBI and ADNI samples, which use different
radioactive tracers for amyloid PET scans. In an effort to
control for discrepancies between studies, we standardized
the log-transformed SUVR measure. Finally, the present
correlation analyses were not adjusted by time of disease
duration, which could be an interesting point for future
studies. Despite that, taking into account that analyses
were conducted separately per clinical stratum, major dif-
ferences are not expected.
In summary, the present data support the role of APOE ε4
as a risk factor of SCD and its involvement in brain amyloid
burden in SCD subjects. Amyloid-PET is an instrumental
measure of the brain amyloid burden endophenotype in
SCD subjects, but the modeling of this important trait will
require further integration of other genetic and epigenetic
factors.
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1. Systematic review: Subjective cognitive decline
(SCD) individuals are at risk of having Alzheimer’s
disease (AD). Despite this, there is a scarcity of
research studying genetic and biomarker profiles of
the SCD population. A comprehensive pubmed
search of previous publications analyzing APOE ef-
fect on SCD subjects was conducted.
2. Interpretation: We evaluated APOE ε4’s effect in the
risk of presenting SCD and analyzed the relationship
between APOE ε4 and cerebral amyloid burden in
SCD using data from the FACEHBI study, one of
the largest single-site SCD cohorts with longitudinal
amyloid PET and cognitive data, and from other in-
dependent SCD and AD cohorts. We detected enrich-
ment of APOE ε4 in the FACEHBI cohort,
suggesting that a pool of AD patients are nested in
this sample and confirmed APOE ε4 is a risk factor
of presenting SCD.
3. Future directions: We found that APOE ε4 only ex-
plains 10% of brain amyloid burden variability in
SCD suggesting that other genetic or epigenetic fac-
tors are involved in this AD endophenotype. Further-
more, the variable relationship between APOE and
brain amyloid burden across clinical diagnoses high-
lights the importance of adjusting for clinical status
when conducting future genome-wide association
studies of cerebral Ab levels.References
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